CPP 2nd Dose Program

CPP member practices can earn an educational grant up to $1,000! It’s as easy as 1, 2, 3...

Knowing is half the battle.

U.S. Adolescents / Teens U.S. Adults
MenACWY
1st Dose
MenACWY
2nd Dose
MenB
1st Dose
MenB
2nd Dose
HPV
1st Dose
HPV
≥ 2 Doses
Prevnar 13
1st Dose
Pneumovax 23
2nd Dose
79% 28% *NEW Category B Recommendation 51% 41% *NEW Recommendation

2014 Stats: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6429a3.htm

  • MenACWY 2nd dose recommendation since 2005: 1st dose at 11-12 years; 2nd dose at 16 years (Ohio school requirement of 2 doses for students entering 12th grade effective fall 2016.)
  • NEW Category B Recommendation for MenB in 2016: 0 & 6 months (Trumenba) or 0 & 1 month (Bexsero) for patients 16-18 years old.
  • HPV 2-dose series recommended: 0 & 6 months for all patients under 15 years
  • NEW Adult Pneumococcal Recommendation in 2014: one dose of Prevnar 13 followed at least 12 months later by one dose of Pneumovax 23 for all adults 65 and older.

Pull the 2nd dose immunization rates from your EMR, practice management system and/or state registry for any of the following immunizations that are offered by your practice:

  • Meningococcal ACWY: % of patients over age 16 who have received 2 doses of Menactra.
    Sample Calculation: Number of patients who have completed their 2nd dose of MenACWY divided by the total number of patients over 16 years old
  • Meningococcal B: % of patients over age 18 who have received 2 doses of Trumenba or Bexsero. Sample Calculation: Number of patients who have completed their 2nd dose of MenB divided by the total number of patients over 18 years old.
  • HPV: % of patients over age 12 who have received at least 2 doses of Gardasil/Gardasil 9.
    Sample Calculation: Number of patients who have completed at least their 2nd dose of HPV divided by the total number of patients over 12 years old
  • Pneumococcal: % of patients over age 66 who have received Prevnar 13 and Pneumovax 23.
    Sample Calculation: Number of patients who have completed both Prevnar 13 and Pneumovax 23 / divided by the total number of patients over 66 years old

Complete a 3-question survey.

Earn your $500 grant.

* Please note CPP will not collect any patient specific information. All immunization rates will be analyzed and reported as general trend data and will not be attributed to an individual practice.

Complete the Initial Survey